ZYME (Zymeworks Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ZYME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Mark Hollywood | EVP & Chief Operating Officer | A | — | — |
| 2026-05-15 | Paul R Schneider | EVP, General Counsel | A | — | — |
| 2026-04-10 | Adam Schayowitz | See Remarks | A | — | — |
| 2026-04-10 | Scott Platshon | EVP, Chief Business Officer | A | — | — |
| 2026-04-07 | Kristin Stafford | EVP, Chief Financial Officer | A | — | — |
| 2026-01-13 | Brian N Cherry | Director | A | — | — |
| 2026-01-13 | Mark Hollywood | EVP & Chief Operating Officer | MIXED | — | — |
| 2026-01-12 | Carlos Campoy | Director | A | — | — |
| 2026-01-12 | Alessandra Cesano | Director | A | — | — |
| 2026-01-12 | Paul Andrew Moore | Chief Scientific Officer | MIXED | — | — |
| 2026-01-12 | Robert E Landry | Director | A | — | — |
| 2026-01-12 | Susan Mahony | Director | A | — | — |
| 2026-01-12 | Kelvin Neu | Director | A | — | — |
| 2026-01-12 | Kenneth Galbraith | Chair & CEO | MIXED | — | — |
| 2026-01-12 | Gregory Austin Ciongoli | Director | A | — | — |
| 2026-01-12 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | — | — |
| 2026-01-07 | LEONE D PATTERSON | EVP, Chief Bus & Fin Officer | A | — | — |
| 2026-01-05 | Kenneth Galbraith | Chair & CEO | MIXED | — | — |
| 2026-01-05 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | — | — |
| 2026-01-05 | Paul Andrew Moore | Chief Scientific Officer | MIXED | — | — |
| 2025-12-22 | Kenneth Galbraith | Chair & CEO | MIXED | — | — |
| 2025-08-12 | Robert E Landry | Director | A | — | — |
| 2025-08-12 | Gregory Austin Ciongoli | Director | A | — | — |
| 2025-06-27 | OLEG NODELMAN | Director | MIXED | — | — |
| 2025-05-19 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-04-18 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-04-07 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-04-02 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-03-27 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-03-24 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-03-19 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-03-13 | OLEG NODELMAN | Director | Buy | — | — |
| 2025-01-21 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2025-01-15 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2025-01-10 | Jeffrey T L Smith | EVP & Chief Medical Officer | A | — | — |
| 2025-01-10 | LEONE D PATTERSON | EVP, Chief Bus & Fin Officer | A | — | — |
| 2025-01-10 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2025-01-10 | Paul Andrew Moore | Chief Scientific Officer | A | — | — |
| 2025-01-10 | Kenneth Galbraith | Chair & CEO | A | — | — |
| 2025-01-06 | Paul Andrew Moore | Chief Scientific Officer | MIXED | — | — |
| 2025-01-06 | Jeffrey T L Smith | EVP & Chief Medical Officer | MIXED | — | — |
| 2025-01-06 | Kenneth Galbraith | Chair & CEO | MIXED | — | — |
| 2025-01-02 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2024-12-27 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2024-12-26 | EcoR1 Capital, LLC | Director | Buy | — | — |
| 2024-12-23 | EcoR1 Capital, LLC | 10%+ Owner | Buy | — | — |
| 2024-12-12 | Derek John Michael Miller | Director | A | — | — |
| 2024-12-12 | Neil Gallagher | Director | A | — | — |
| 2024-12-12 | Nancy Davidson | Director | A | — | — |
| 2024-12-12 | Carlos Campoy | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 22,970,388 | — |
| — | Director | 15,720,161 | — |
| — | 10%+ Owner | 1,827,101 | — |
| — | Director | 493,500 | — |
| — | Chief Executive Officer | 357,027 | — |
| — | Chair & CEO | 257,266 | — |
| — | EVP & Chief Operating Officer | 133,852 | — |
| — | Chief Scientific Officer | 48,497 | — |
| — | Chief Scientific Officer | 36,407 | — |
| — | EVP & Chief Medical Officer | 36,018 | — |
| — | President & COO | 20,709 | — |
| — | Chief Medical Officer | 14,449 | — |
| — | Director | 7,500 | — |
| — | Chief Medical Officer | 7,377 | — |
| — | SVP & Chief Financial Officer | 6,503 | — |
| — | Chief People Officer | 6,350 | — |
| — | Chief Commercial Officer | 2,513 | — |
| — | See Remarks | 800 | — |
| — | EVP, Chief Bus & Fin Officer | 459 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZYME quote page; the site-wide leaderboard is on the insider transactions hub.